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Background. We aimed to describe the clinical characteristics and outcomes of patients treated with meropenem-vaborbactam 
(MEV) for a variety of gram-negative infections (GNIs), primarily including carbapenem-resistant Enterobacterales (CRE).
Methods. This is a real-world, multicenter, retrospective cohort within the United States between 2017 and 2020. Adult pa-
tients who received MEV for ≥72 hours were eligible for inclusion. The primary outcome was 30-day mortality. Classification and 
regression tree analysis (CART) was used to identify the time breakpoint (BP) that delineated the risk of negative clinical outcomes 
(NCOs) and was examined by multivariable logistic regression analysis (MLR).
Results. Overall, 126 patients were evaluated from 13 medical centers in 10 states. The most common infection sources were respira-
tory tract (38.1%) and intra-abdominal (19.0%) origin, while the most common isolated pathogens were CRE (78.6%). Thirty-day mor-
tality and recurrence occurred in 18.3% and 11.9%, respectively. Adverse events occurred in 4 patients: nephrotoxicity (n = 2), hepatoxicity 
(n = 1), and rash (n = 1). CART-BP between early and delayed treatment was 48 hours (P = .04). MEV initiation within 48 hours was 
independently associated with reduced NCO following analysis by MLR (adusted odds ratio, 0.277; 95% CI, 0.081–0.941).
Conclusions. Our results support current evidence establishing positive clinical and safety outcomes of MEV in GNIs, including 
CRE. We suggest that delaying appropriate therapy for CRE significantly increases the risk of NCOs.
Keywords.  carbapenem-resistant Enterobacterales; gram-negative infections; meropenem-vaborbactam; multidrug-resistant.
The prevalence of carbapenem-resistant Enterobacterales 
(CRE) has increased dramatically over recent years, causing 
>13  000 nosocomial infections and contributing to >1000 
deaths annually in the United States [1]. CRE requires novel 
antibiotics with activity against these multidrug-resistant 
(MDR) organisms. Klebsiella pneumoniae carbapenemase 
(KPC) is an Ambler class A enzyme that utilizes serine at the 
active site to hydrolyze almost all beta-lactam (BL) antibiotics 
and is the most prevalent carbapenemase in the United States 
[2]. Combination therapy (CT) with 2 or even 3 antibiotics has 
become the standard of care for suspected CRE by necessity 
[3]. However, this historical approach is now challenged by the 
arrival of novel anti-CRE agents with established efficacy and 
improved safety profiles, particularly in high-risk patients (ie, 
those with chronic renal insufficiency and/or immunocompro-
mised), who ultimately better represent the patient population 
with CRE [1, 4, 5].
Meropenem-vaborbactam (MEV) is a novel boronic 
acid beta-lactamase inhibitor (BLI) combined with a well-
known carbapenem that exhibits activity against MDR 
Enterobacterales, including KPC-producing strains [6]. 
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The US Food and Drug Administration (FDA) approved 
MEV for the management of complicated urinary tract in-
fections on the basis of the TANGO I trial [7, 8]. In TANGO 
I, MEV was associated with improved overall success (de-
fined as clinical cure or improvement and microbiological 
eradication) when compared with piperacillin-tazobactam 
meeting the prespecified margin for noninferiority. In an-
other trial, TANGO II, MEV was associated with improved 
clinical cure, decreased mortality, and decreased adverse 
events when compared with the best available therapy 
against a variety of CRE infections [9]. Since then, MEV has 
been used in clinical practice at a wider scale and for indica-
tions beyond those evaluated in the TANGO I and TANGO 
II trials [8]. Noninferiority studies do not optimally address 
outcomes in specific patient populations where new agents 
maybe most beneficial [10, 11]. This introduces a tremen-
dous challenge for clinicians when attempting to extrapolate 
the results of noninferiority clinical trials to patients who 
were excluded from them. In fact, these patients benefit the 
most from these novel agents in a real-world setting. Thus, 
real-world studies that are conducted after initial drug ap-
proval are essential for clinicians, as they provide invaluable 
health outcomes information regarding the utility of newly 
approved drugs in specific conditions and/or patient popu-
lations beyond conventional randomized controlled trials 
(RCTs) and tend to include those who are older, have more 
critical illness or a more immunocompromised state, or 
have chronic end organ damage such as renal insufficiency 
[10, 12, 13]
Therefore, we sought to describe the clinical characteristics, 
microbiology, and clinical outcomes of patients treated with 
MEV for MDR gram-negative infections (GNIs) in the real-
world setting.
METHODS
Study Design and Population
We conducted a retrospective, multicenter study at 13 academic 
and community centers in the United States between September 
2017 and July 2020. Patients were eligible for inclusion if they 
met the following criteria: (1) age ≥18 years and (2) receipt of 
≥72 hours of MEV for suspected or confirmed MDR GNIs. 
Only the first eligible MEV treatment course during the study 
period was included.
Ethical Review
This study design and work were reviewed and approved by 
the Wayne State University Human Investigational Review 
Board and the DMC Research Review Committee before 
initiation.
Patient Consent 
Patient consent was not required for this retrospective analysis.
Data Collection and Study Definitions
For eligible patients, demographics, comorbid conditions, mi-
crobiology, and clinical and treatment data were extracted 
from the electronic medical record and entered into Research 
Electronic Data Capture (REDCap; Vanderbilt University) [14]. 
All cultures, bacterial identifications, and antibiotic susceptibil-
ities were performed at each center according to local proced-
ures. Minimum inhibitory concentration (MIC) results were 
interpreted per the Clinical and Laboratory Standards Institute 
(CLSI), and CRE were defined as Enterobacteriaceae interme-
diate or resistant to carbapenems using the current US Centers 
for Disease Control and Prevention criteria [15]. MEV sus-
ceptibility testing was done using Etest or Liofilchem based on 
availability. Variables associated with GNI as well as infection 
source were determined based on clinical notes and microbio-
logical/diagnostic reports. Onset of GNI was based on the date 
and time when the index culture was collected. The Charlson 
Comorbidity Index (CCI) was used to measure the degree of 
patient comorbidity. Severity of illness was assessed using the 
Acute Physiology and Chronic Health evaluation II (APACHE 
II) score and the Sequential Organ Failure Assessment (SOFA) 
score at GNI onset [16, 17]. Creatine clearance (CrCl) and 
glomerular filtration rate (GFR) were calculated based on the 
Cockcroft-Gault and Chronic Kidney Disease–Epidemiology 
Collaboration equations, respectively [18]. The CrCl was cal-
culated relative to the index culture. Because the GFR is the 
primary recommendation for MEV dosing, it was calculated 
relative to the MEV start time. Appropriate, under–, or over–
renally adjusted doses of MEV were defined according to the 
GFR package insert instructions [19]. Nephrotoxicity was de-
fined as an increase in serum creatinine (≥0.5 mg/dL or ≥50% 
from baseline, whichever was greater, on 2 consecutive meas-
urements while on MEV and up to 72 hours following the last 
dose). Nosocomial GNIs were defined as infections with index 
culture obtained ≥48 hours after admission. CT was defined as 
receiving a concomitant gram-negative targeted antibiotic for 
≥48 hours with MEV. Recurrence was defined as microbiolog-
ical recurrence while on treatment or within 30 days of the end 
of MEV treatment.
Outcome
The primary outcome was 30-day mortality. Secondary clinical 
end points included 90-day mortality, 30-day recurrence, and 
hospital length of stay. Safety outcomes that were presumed to 
be attributable to MEV included nephrotoxicity, dermatolog-
ical reactions, hematological reactions, central nervous system 
disturbances, gastrointestinal (GI) intolerances, Clostridioides 
difficile–associated diarrhea, and others. All clinical and safety 
outcome time points were measured from time of culture col-
lection. Nephrotoxicity was evaluated in patients not receiving 
renal replacement therapy or in hemodialysis patients at the 
time of MEV initiation.
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Statstical Analysis
Descriptive statistics were used to evaluate patients’ demo-
graphics. Nominal data were reported as percentages and fre-
quencies, and continous data were reported as medians and 
interquartile ranges (IQRs) or means and SDs, as appropiate. 
The t test and Mann-Whitney U were used for continous vari-
ables that were parametric and nonparametric, respetively, as 
appropiate. Classification and regression tree (CART) anal-
ysis was performed to determine the time to start MEV that 
was most predicitve of negative clinical outcomes (NCOs). In 
this analysis, patients with unknown index culture dates were 
excluded. Additionally, because we are assessing the impact 
of timely initation of MEV only, patients who received other 
appropriate antibiotics for GNIs were excluded. Negative clin-
ical outcomes were defined as 30-day mortality and/or 30-day 
microbiological recurrence measured from the index culture 
collection date. Time to start MEV, along with all the variables 
associated with NCOs, was assessed in a similar manner to 
the primary analysis. When performing CART, the minimum 
parent node was specified at 30 cases, and the terminal node 
at 15 cases. Multivariable logistic regression was used to assess 
the independent predictors of NCOs while adjusting for con-
founding variables. Clinically relevant variables were selected 
for model entry based on bivariate analysis at a P value <.2; when 
the number of patients in subgroups was too small to allow for 
meaningful analysis, the subgroups were collapsed into single 
composite variables. These variables were entered into the 
model simultaneously and removed using a backward stepwise 
approach. Covariates were retained in the model if the P value 
for the likelihood ratio test for their removal was <.1. The vari-
ance inflation factor was used to assess the multicollinearity of 
covariates in the model, with values in the acceptable range of 
1–5 considered acceptable. The Hosmer-Lemeshow goodness-
of-fit test was used to assess the model’s fit. All tests were 
2-tailed, with P values ≤.5 considered statistically significant. 
IBM SPSS software, version 26.0 (SPSS, Inc., Chicago, IL, USA), 
was used for all analyses.
RESULTS
Patient Baseline Demographics and Clinical and Infection Characteristics
Demographics
Overall, 126 patients were included from 13 academic medical 
centers and community hospitals located in 10 states. A  de-
scription of patient baseline, clinical, and infection character-
istics is displayed in Table 1. In general, patients had a median 
age (IQR) of 56.0 (37.0–68.0) years and were mostly male (79, 
62.7%) and of Caucasian race (60, 47.6%). Patients had a high 
burden of medical comorbidity, with a median APACHE II 
score (IQR) of 18.0 (12.0–26.0), a median SOFA score (IQR) 
of 7 (4–10), and a median CCI score (IQR) of 4.0 (2.0–6.0). 
The CrCl median (IQR) was 28.3 (20.1–55.7) mL/min, and the 
Table 1. Baseline Demographics and Clinical and Infection Criteria
Criteriaa Population (n = 126)
Demographics 
Age, y 56.0 (37.0–68.0)
Age ≥65 y 39 (31.0)
Sex, male 79 (62.7)
Race
 African American 45 (35.7)
 Caucasian 60 (47.6)
 Others 21 (16.6)
Weight, kg 82.5 (63.7–102.5)
BMI 28.5 (22.5–33.7)
 BMI ≥30 kg/m2 50 (39.7)
Baseline serum creatinine 0.9 (0.7–1.7)
CrCl 28.3 (20.1–55.7)
 Crcl >50 mL/min 33 (26.2)
 Crcl 30–49 mL/min 29 (23.0)
 Crcl 15–29 mL/min 50 (39.7)
 Crcl <15 mL/min 14 (11.1)
Residence before admission
 Home 65 (51.6)
 Transfer from outside hospital 33 (26.2)
 Nursing home, skilled nursing facility, long-term 
care facility
23 (18.3)
 Others 5 (3.9)
Comorbid conditions 
Cerebrovascular diseaseb 13 (10.3)
Chronic pulmonary diseasec 21 (16.7)
Moderate to severe kidney disease or on 
chronic dialysis 
37 (29.4)
Chronic dialysisd 20 (15.9)
Connective tissue diseasee 8 (6.3)
Cystic fibrosis 10 (7.9)
Dementia 6 (4.8)
Diabetes disease, any 50 (39.7)
 Without end organ damage 17 (13.5)
 With end organ damage 33 (26.2)
Heart failure 27 (21.4)
Hemiplegia 8 (6.3)
Immunodeficient condition, any 
 AIDS (CD4 <200) 1 (0.8)
 HIV 2 (1.6)
 Leukemia 1 (0.8)
 Lymphoma 1 (0.8)
 Tumor without metastasis 8 (6.3)
 Tumor with metastasis 7 (5.6)
Liver disease, any 17 (13.5)
 Mildf 5 (4.0)
 Moderate or severe liver diseaseg 12 (9.5)
Myocardial infarction 12 (9.5)
No conditions 5 (4.0)
Peptic ulcer disease 1 (0.8)
Peripheral vascular diseaseh 20 (15.9)
MDR risk factors 
Admitted from nursing home or extended care 
facility 
18 (14.3)
Chronic dialysis in 30 d before index culture 20 (15.9)
Colonization with resistant organisms 21 (16.7)
Home infusion 2 (1.6)
Home wound care 4 (3.2)
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majority had a CrCl of 15–29 mL/min (50, 39.7%). The GFR 
median (IQR) was 67.5 (28.0–116.5) mL/min/1.73 m2, and the 
majority had a GFR of ≥50 mL/min/1.73 m2 (71, 56.4%). The 
most common MEV dose was 4 g every 8 hours (60, 51.7%), 
followed by 2 g every 12 hours (27, 23.3%). Overall, 81 (64.2%) 
received the appropriate dose based on renal function, 25 
(19.8%) received lower doses, and 20 (15.8%) received higher/
wrong doses. Nearly half of the cohort (62, 49.2%) was residing 
in the intensive care unit (ICU) at any point. The majority 
of patients had been exposed to prior antimicrobials for >24 
hours in the 90 days before index culture (88, 69.8%), and pa-
tients were often previously infected with an MDR organism 
(49, 38.9%). Overall, patients with CRE (n = 99) shared similar 
demographics and clinical and infection characteristics with 
the entire cohort.
Infection Characteristics
The most common infection sources were respiratory tract (48, 
38.1%), intra-abdominal (24, 19.0%), and urinary tract (17, 
13.5%). Most of the infections (74, 58.7%) were nosocomial, 
with a median time from admission to index culture collection 
(IQR) of 19.8 (7.68–33.74) days. Polymicrobial infections were 
Criteriaa Population (n = 126)
Prior antimicrobials >24 h in 90 d before index 
culture
88 (69.8)
Prior infection with resistant organisms 49 (38.9)
Prior hospitalization for at least 48 h in 90 d be-
fore index culture 
83 (65.9)
Prior surgery in 30 d preceding index culture 16 (12.7)
PWID 8 (6.3)
Sources of infection 
 Bone and joint 3 (2.4)
 Infective endocarditis 1 (0.8)
 Intraabdominal 24 (19.0)
 Intravenous catheter 4 (3.2)
 Otherj 2 (1.6)
 Primary bacteremia 12 (9.5)
 Pneumonia 48 (38.1)
 Mechanically ventilated for 48 h before 
pneumoniai
25 (19.8)
 Skin and soft tissue 13 (10.3)
 Urinary 17 (13.5)
 Unknown 2 (1.6)
Pathogens targeted 
 Carbapenem-resistant pathogen 99 (78.6)
 Acinetobacter baumannii 2 (1.6)
 Citrobacter freundii 4 (3.2)
 Enterobacter cloacae 21 (16.7)
 Escherichia coli 25 (19.8)
 Klebsiella aerogenes 3 (2.4)
 Klebsiella oxytoca 4 (3.2)
 Klebsiella pneumoniae 53 (42.1)
 Morganella morganii 1 (0.8)
 Proteus mirabilis 4 (3.2)
 Pseudomonas aeruginosak 11 (8.7)
 Serratia marcescens 4 (3.2)
 Stenotrophomonas maltophilia 1 (0.8)
Markers of disease progression 
APACHE II 18.0 (12.0–26.0)
 APACHE ≥30 15 (11.9)
CCI 4.0 (2.0–6.0)
 CCI ≥5 54 (42.9)
MEV dosing 
 4 g every 8 h 61 (48.7)
 Correct dose 55 (77.5)
 2 g every 8 h 31 (24.6)
 Correct dose 8 (57.1)
 2 g every 12 h 8 (6.3)
 Correct dose 5 (25.0)
 1 g every 12 h 23 (18.3)
 Correct dose 13 (61.9)
 Othersl 3 (2.4)
Others factors
 Inhaled antibiotics, any 20 (15.9)
 Aztreonam 1 (0.8)
 Colistin 13 (10.3)
 Tobramycin 6 (4.8)
 Combination therapy for ≥48 hm 43 (34.1)
 Amikacin 9 (7.1)
 Aztreonam 6 (4.8)
 Ciprofloxacin 1 (0.8)
Criteriaa Population (n = 126)
 Colistin 5 (4.0)
 Gentamicin 2 (0.6)
 Levofloxacin 7 (5.6)
 Minocycline 6 (4.8)
 Polymyxin B 5 (4.0)
 Tigecycline 2 (1.6)
 TMP-SMX 5 (4.0)
 Tobramycin 6 (4.8)
 Othersn 4 (3.2)
 Intensive care upon index culture 62 (49.2)
 SOFA score 7 (4–10)
Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation; BMI, body 
mass index; CCI, Carlson Comorbidity Index; CD4, cluster of differentiation 4; COPD, 
chronic obstructive pulmonary disease; DVT, deep venous thrombosis; IQR, interquar-
tile range; MDR, multidrug resistant; MEV, meropenem-vaborbactam; OA, osteoarthritis; 
PWID, person who inject drugs; SOFA, Sequential Organ Failure Assessment; TIA, tran-
sient ischemic attack. 
aData presented as median (IQR) and/or n (percentages) as appropriate
bStroke or TIA.
cAsthma or COPD.
dHemodialysis or peritoneal dialysis.
eOA or rheumatic arthritis.
fChronic hepatitis without cirrhosis.
gPortal hypertension or cirrhosis.
hDVT, chronic venous disease.
iSuggestive of ventilator-associated pneumonia.
jOther included prosthetic arteriovenous graft (n = 1), retroperitoneal infection (n = 1).
kOnly 8 patients were targeted by MEV only for Pseudomonas aeruginosa, while the re-
maining (n = 3) patients had other pathogens that were primarily targeted by MEV.
ln = 1, each, received 4 g q12, 2 g q24, and 1 g q24.
mCombination therapy occurred in 7 (87.5%) patients with P. aeruginosa and 36 (30.5%) 
patients with other pathogens.
nOthers include ampicillin-sulbactam, cefepime, doxycycline, and eravacycline (n = 1, each).
Table 1. Continued Table 1. Continued
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identified in 15 (11.9%) patients. Positive blood cultures were 
demonstrated in 40 (31.7%) patients (n  =  12 primary bacte-
remia, n  =  9 intra-abdominal source, n  =  8 respiratory tract, 
n = 4 intravenous catheter, n = 3 urinary tract, n = 1 infective 
endocarditis, n = 2 unknown, n = 1 other).
A total of 232 GN isolates were cultured from the entire 
cohort. CRE were isolated in 99 (78.6%) culture specimens. 
The majority were K.  pneumoniae (53/99, 53.5%), followed 
by Escherichia coli (25/99, 25.3%), Enterobacter spp. (24/99, 
24.2%), and Citrobacter freundii (4/99, 4%).
Among strains that were tested for MEV susceptibility, 
K. pneumoniae (n = 43), E. cloacae (n = 16), and E. coli isolates 
(n  =  15), the MIC50 (range) was 0.064/8 (0.032/8–8/8) mg/L, 
0.38/8 (0.047/8–6.00/8) mg/L, and 0.219/8 (0.023/8–4.0/8) 
mg/L, respectively. For P. mirabilis (n = 3), the MIC50 (range) 
was 0.094/8 (0.064/8–0.25/8) mg/L. For P. aeruginosa (n = 2), 
the MIC50 (range) was 18.0 (4/8–32/8). For A.  baumannii 
(n = 1), C. freundii (n = 1), and M. morganii (n = 1), the MIC50 
was 256/8, 0.094/8, and 0.38/8, respectively. The S. marcescens 
MEV MIC50 was not reported.
Among strains that were tested for ceftazidime/avibactam 
(CZA) susceptibility, the MIC50 (range) was 2.0/4 (0.25/4–
256/4) mg/L for K. pneumoniae (n = 43), 3.0/4 (0.25/4–256/4) 
mg/L for E. cloacae (n = 14), and 0.75/4 (0.125/4–256/4) mg/L 
for E. coli (n = 15) isolates. As for P. aeruginosa (n = 5), the CZA 
MIC50 (range) was 16/4 (2.0/4–256/4). For P. mirabilis (n = 2), 
the CZA MIC50 (range) was 0.185/4 (0.12/4–0.25/4) mg/L, 
while for C. freundii (n = 2) it was 2.75/4 (1.5/4–4/4) mg/L. The 
A. baumannii and S. marcescens isolates had a CZA MIC50 of 
256/4 and ≤8/4 mg/L, respectively. The M. morganii CZA MIC50 
was not reported.
Among non-CRE strains (n  =  27) that were tested for 
meropenem susceptibility, the MIC50 was 0.125 (0.125–4) for 
E. coli (n = 4), 6 [4–8] for P. aeruginosa (n = 2), 8 for A. baumannii 
(n = 1), and 0.125 for for K. pneumoniae (n = 1).
Infection Treatment Course and Clinical Outcomes
Nearly all patients received an infectious diseases (ID) consul-
tation (125, 99.2%), and the majority were consulted within 48 
hours (93, 73.8%). In all sites (n = 13), MEV requires ID con-
sult and/or stewardship approval. Nearly a third of patients (39, 
31.0%) received a surgical consult, and among these, 31 (24.6%) 
received a surgical intervention. Further MEV treatment in-
formation is described in Table 2. Over half of patients (74, 
58.7%) did not have follow-up cultures. Only 34.1% of MEV 
patients were on CT; of these, only 6 had polymicrobial infec-
tions. Patients’ outcomes are described in Table 3. In the en-
tire cohort, 30-day mortality occurred in 23 (18.3%) patients. 
Among those (n  =  23), only 12 (52.2%) received the appro-
priate package insert–recommended dose based on renal func-
tion, while 7 (5.5%) received lower doses and 4 (3.2%) received 
higher doses. Additionally, only 3 (13.0%) had polymicrobial in-
fections, 16 (69.6%) had nosocomial infections, and 22 (95.7%) 
received monotherapy with MEV for the GNI. No patients with 
A. baumannii (n = 2) experienced 30-day or 90-day mortality. 
Infection sources among patients who experienced 30-day 
mortality (n = 23) were respiratory (n = 12), intra-abdominal 
(n = 4), primary bacteremia (n = 2), skin and soft tissue (n = 2), 
unknown (n = 2), and urinary tract (n = 1). Thirty-day recur-
rence occurred in 15 (11.9%), where recurrence occurred in 4 
during treatment with MEV and in 11 within 30 days of the end 
of treatment.
Thirty-day readmission occurred in 23 (18.3%), and 90-day 
mortality occurred in 40 (31.7%) patients. The median length 
of hospital stay (IQR) was 34.5 (17.8–62.3) days. None of the 
isolates from patients with available repeat cultures (n  =  25) 
demonstrated MEV resistance. As illustrated in Table 3, out-
comes were fairly similar between patients who had CRE and 
Pseudomonas spp. isolated.
At least 1 adverse event was documented for 4 (3.1%) patients. 
These included acute kidney injury in 2 (1.6%) patients and severe 
Table 2. Treatment-Related Outcomes
Variablea Total Study (n = 126) PsA Spp. (n = 8)b Non PsA Spp. (n = 118) CRE Spp. (n = 99)
Active antibiotics before MEVc 31 (24.6) 4 (50.0) 27 (22.9) 24 (24.2)
Time to active antibiotics, h 14.3 (0.0–75.5) 41.7 (0.05–83.2) 14.3 (0.0–74.3) 36.5 (0.75–75.2)
ID consult 125 (99.2) 7 (87.5) 118 (100) 99 (100.0)
ID consult within 48 h 93 (73.8) 6 (75.0) 87 (73.7) 71 (71.7)
Time to ID consult, h 6.7 (0.0–48.9) 0.0 (0.0–8.3) 8.6 (0.0–52.5) 11.1 (0.0–56.8)
Surgical consult 39 (30.9) 3 (37.5) 36 (30.5) 35 (35.4)
Source controld 40 (31.7) 3 (37.5) 37 (31.4) 35 (35.4)
Time to MEV, h 78.6 (29.8–124.3) 81.9 (56.2–116.7) 78.6 (28.5–126.57) 85.1 (48.6–133.1)
MEV duration, d 11.7 (5.9–15.2) 14.4 (5.3–15.2) 11.7 (6.0–14.9) 11.8 (6.7–16.0)
Abbreviations: ID, infectious diseases; MEV, meropenem vaborbactam; PsA, Pseudomonas aeruginosa.
aAll values represent number (%) or median (interquartile range).
bPatients were grouped in this group if Pseudomonas aeruginosa was the only pathogen targeted by MEV. There are (n = 3) patients with Pseudomonas aeruginosa and other pathogens 
who are grouped in others (n = 118)
cActive antibiotics were amikacin (n = 7), cefepime (n = 2), ceftazidime-avibactam (n = 11), ciprofloxacin (n = 3), ertapenem (n = 1), levofloxacin (n = 1), meropenem (n = 4), piperacillin-
tazobactam (n = 1), polymyxin B (n = 2), tigecycline (n = 2), TMP-SMX (n = 1), tobramycin (n = 1), other (n = 1).
dSource control includes the following: debridement (n = 10), intravenous catheter removal (n = 3), valvular repair (n=1), new prosthetic valve (n = 1), amputation (n = 1), other (n = 19).
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dermatological reaction and hepatotoxicity in 1 (0.8%) patient 
each. The case of severe dermatological reaction was reported 
and described prior (Alosaimy et al [8]). Among patients who 
experienced adverse events (n = 4), 2 (50%) were on CT. Patients 
were mostly discharged to home (36, 28.5%) or skilled nursing 
facilities (SNFs)/long-term care facilities (LTACs; 45, 35.7%).
In order to perform CART analysis, patients who received ap-
propriate antibiotics for GNI other than MEV and patients with 
unknown index culture dates were excluded (n  =  35). Overall, 
91 patients were included in this subanalysis. When CART 
analysis was performed, the time breakpoint for NCO was >48 
hours (Figure 1). Upon multivariable logistic regression anal-
ysis, timely MEV administration was independently associated 
with fewer NCOs (ie, within 48 hours; odds ratio, 0.277; 95% CI, 
0.081–0.941) (Table 4). Other independent predictors of NCOs 
included APACHE II scores, nosocomial infections, heart failure, 
and intra-abdominal infections. Examination of the different time 
delays to appropriate therapy within the 48-hour CART-derived 
breakpoint is shown in Figure 1. Of the 91 patients, 11 received 
MEV within 12 hours, 9 received MEV within 12–24 hours, and 
14 received MEV within 24–48 hours. In Figure 2, we stratify pa-
tients outcomes by delay in receiving appropriate therapy.
DISCUSSION
The increase in prevalence of CRE infections continues 
to burden clinicians, and the lack of effective and safe 
antimicrobials against these pathogens exacerbates this con-
cern [4, 5]. These patient populations typically have substantial 
comorbidities and experience high mortality and low clinical 
cure rates with historical antibiotics, reflecting the immediate 
need for improved antibiotic treatment agents demonstrating 
clinical evidence of positive outcomes [4, 5, 20]. After initial 
approval of these agents, real-world observational studies are 
fundamental, as they provide valuable clinical outcomes data 
beyond that reported in most large registrational trials [10, 12, 
13]. Extrapolating efficacy and safety data from the limited 
patient populations and small sample sizes in RCTs to real-
world, underserved, and seriously ill patients is challenging. 
Ultimately, real-world data can better represent patients who 
are encountered by clinicians in their daily practice, who are 
often excluded in registrational RCTs [12, 13].
Our patient population represented a high-risk group; 
roughly a third of our patients were age 65 years and older, a 
third had moderate to severe kidney disease or were on dial-
ysis, ~40% were obese, and many had pneumonia or primary 
bacteremia as a source of infection. MDR risk factors were 
common in our study, as almost 70% of patients received 
prior antimicrobials and experienced previous hospitali-
zation. This underscores the significance of our study find-
ings, as these variables exemplify the real-world patient who 
is typically excluded from RCTs. The proportion of patients 
who experienced mortality in our study was 18.3%, which 
Table 3. Clinical Outcomes Overview
Outcomea
Total Study  
(n = 126) PsA Spp. (n = 8) Non-PsA (n = 118)
CRE Spp.  
(n = 99)
Efficacy 
30-d mortality 23 (18.3) 0 (0) 23 (19.5) 19 (19.2)
90-d mortality 39 (33.1) 1 (12.5) 40 (31.7) 34 (34.3)
In-hospital mortality 30 (23.8) 1 (12.5) 29 (24.6) 25 (25.3)
30-d recurrence 15 (11.9) 2 (25.0) 13 (11.0) 13 (13.1)
30-d readmission 23 (18.3) 0 (0) 23 (19.5) 21 (21.2)
Worsen or failure to improve while on MEV 30 (23.8) 2 (25.0) 28 (23.7) 25 (25.3)
Development of MEV resistance (n = 25) 0 (0) 0 (0) 0 (0) 0 (0)
Length of hospital stay, d 34.5 (17.8–62.3) 37.0 (14.5–95.5) 34.5 (18.0–62.3) 40.0 (18.0–64.0)
Safety
Any adverse event 4 (3.2) 1 (12.5) 3 (2.5) 2 (2.0)
Acute kidney injuryb 2 (1.6) 0 (0) 2 (1.7) 2 (2.0)
Clostridioides difficile infection 0 (0) 0 (0) 0 (0) 0 (0)
Hepatoxicityc 1 (0.8) 1 (12.5) 0 (0) 0 (0)
Severe dermatological reaction 1 (0.8) 0 (0) 1 (0.8) 1 (1.0)
Discharge disposition 
Home 36 (28.5) 5 (62.5) 31 (26.2) 22 (22.2)
SNF/LTAC 45 (35.7) 2 (25.0) 43 (36.4) 37 (37.4)
Inpatient rehabilitation facility 8 (6.3) 0 (0) 8 (6.8) 8 (8.1)
Hospice 8 (6.3) 0 (0) 8 (6.8) 7 (7.1)
Abbreviations: ALT, alanine aminotransferase; AST, alanine aminotransferase; CRE, carbapenem-resistant Enterobacterales; MEV, meropenem vaborbactam; LTAC, long-term care facilities; 
PsA, Psedomonas aeruginosa; SNF, skilled nursing facility; ULN, upper limit of normal.
aAll values represent number (%) or median (interquartile range).
bPatients receiving hemodialysis excluded. None of the patients who experienced nephrotoxicity were on a concomitant nephrotoxin.
cDefined as an elevation in the serum concentration of ALT, AST exceeding 2× the ULN [29].
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is somewhat comparable to what was reported in TANGO 
II and other published MEV real-world studies (ie, 7.5% to 
15.6%) [8, 9, 21, 22].
It is important to note several differences between our co-
hort and previously published MEV real-world studies [8, 21, 
22]. First, only 48.7% of our patients were on the full MEV 
dose, vs 54.7%–69.3% on other anti-CRE agents in real-world 
studies [23–25]. Notably, renally adjusted doses of these novel 
agents are common in real-world studies in various GNIs and 
range from 30% to 45% [23–25]. Additionally, only 55 (43.7%) 
and 26 (20.6%) patients in our study received appropriate full 
and reduced MEV doses, respectively. Remarkably, only 12 
(52.2%) patients who experienced 30-day mortality received 
the appropriate package insert–recommended dose based on 
renal function. The impact of renal dose adjustment, partic-
ularly when BL/BLI antibiotics are inappropriately adjusted 
upon clinical failure, might be more pronounced in patients 
with certain infections and/or higher minimum inhibitory 
concentrations.
Additionally, we included patients who received MEV 
for MDR pathogens other than CRE, including 2 cases of 
A.  baumannii and 8 cases of P.  aeruginosa in our cohort. To 
the best of our knowledge, this is the largest study of patients 
with these infections treated with MEV for these organisms. 
Although the clinical outcomes of these 10 isolates were posi-








NCO: negative clinical outcome defined as 30-day mortality and/or 30-day recurrence











NODE 2: ≤ 48 hours NODE 3: > 48 hours
N = 91, n (%)
N = 34, n (%) N = 57, n (%)
Figure 1. Classification and regression tree analysis–derived meropenem-vaborbactam initiation time breakpoint for negative clinical outcomes. aThe time breakpoint 
illustrated was the only time breakpoint identified by classification and regression tree analysis Abbreviation: NCO, negative clinical outcome, defined as 30-day mortality 
and/or 30-day recurrence.
Table 4. Independent Predictors of Negative Clinical Outcomes
Variable OR (95% CI) P Value aOR (95% CI) P Value
Timely MEVa 0.387 (0.098–1.522) .174 0.277 (0.081–0.941) .040
APACHE II score 1.083 (1.012–1.159) .021 1.095 (1.029–1.166) .004
Nosocomial infectionb 2.298 (0.583–9.055) .234 4.041 (1.132–14.426) .031
Heart failure 5.313 (1.188–23.763) .029 4.216 (1.129–15.733) .032
Intra-abdominal infection 0.162 (0.022–1.206) .076 0.151 (0.027–0.835) .030
Hosmer-Lemeshow goodness-of-fit: 0.302. Variance inflation factor for all factors in the model: 1–5. Variables in the model: age, APACHE, admission from nursing home, CCI, chronic kidney 
disease, chronic dialysis, dementia, heart failure, timely MEV, tumor without metastasis, source is an intra-abdominal infection, source is a respiratory tract infection, liver disease, nosoco-
mial infection, surgery within the past 30 days of index culture.
Abbreviations: APACHE II, Acute Physiology and Chronic Health Evaluation; CCI, Charlson Comorbidity Index; CART, classification and regression tree analysis; MEV, meropenem 
vaborbactam.
aTimely MEV is defined as MEV within 48 hours (ie, at CART breakpoint).
bDefined as infection within 48 hours of inpatient admission date/time.
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Of interest, the use of CT in our study (34.1%) was similar to 
what was previously reported in other real-world data with BL/
BLIs in various GNIs (24.7%–39.7%) [23–25]. The use of CT is 
controversial, particularly for the treatment of CRE infections 
and particularly with new CRE agents, as they lack sufficient 
data to demonstrate improved clinical outcomes and carry a 
higher risk of toxicities, particularly nephrotoxicity with agents 
such as polymyxin-based therapy and/or aminoglycosides [1, 
3, 4, 23, 24]. In our study, 50% of patients who experienced ad-
verse events were on CT; nevertheless, the number (n = 4) is 
too small to draw specific conclusions. Overall, our safety out-
comes were favorable, with only 3.2% of patients experiencing 
any adverse event attributable to MEV, and this rate is signifi-
cantly lower than the rates reported in RCTs and observational 
studies [7, 9, 21].
The time to initiate MEV (ie, 79 hours) in our study was 
similar to what we have previously found in other compar-
ator CRE agents at around 72–96 hours [23, 24]. We found an 
association between starting MEV within 48 hours of culture 
collection and patient survival [26]. This adds to the body of 
literature that demonstrates that early (ie, within 48 hours) in-
itiation of appropriate therapy in GNI is essential for patient 
survival [27, 28].
Similar to previously published studies, a significant propor-
tion of real-world patients in our study had bacteremia and/
or pneumonia [21, 22]. Such infections are associated with a 
high bacterial burden and poor clinical outcomes. Additionally, 
infectious diseases and surgery consultations were common 
in our cohort. This closely resembles real-world practice, 
where multidisciplinary teams are involved with the decision 
for source control as well as the approval/restriction of new 
broad-spectrum agents.
Our study is not without limitations. Real-world studies are 
subject to inherent biases and limitations related to their ret-
rospective design and reliance on medical chart review. First, 
important information such as results of follow-up cultures 
was not available for all patients. However, this is reflective of 
real-world practice, where clinicians may not routinely obtain 
follow-up cultures. Therefore, it remains unclear when patients 
cleared their infection or if they ultimately developed MEV re-
sistance, particularly with the absence of MEV susceptibility. 
Third, our study lacked a comparator arm, hindering our ability 
to interpret the effectiveness and safety of MEV compared with 
other anti-CRE agents. Additionally, because our methodology 
included only patients who received MEV for a minimum of 
72 hours, we may have excluded patients who received MEV 
briefly and did not respond well (ie, switched to alternative anti-
CRE agents or died). Of interest was the relatively low MIC50 
for CZA in our cohort. It remains unknown if these patients 
would have had favorable clinical outcomes if treated with 
CZA rather than MEV. Lastly, we were not able to find suffi-
cient data regarding the mechanisms responsible for antibiotic 
resistance, particularly as we did not detect resistance in the few 
isolates tested.
In conclusion, our multicenter observational study adds to 
the existing literature describing health outcomes in patients 
treated with MEV for serious GNIs, including CRE, from geo-
graphically diverse health care settings and underscores the im-
portant need for continued research with this agent in various 
types of GNI.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility 






































≤12 hours 12–24 hours 25–37 hours
Delay in appropriate therapy (hours)
38–48 hours* 49–61 hours >61 hours
*Indicates 0% negative clinical outcomes, 0% 30-day mortality and 0% 30-day recurrence
Figure 2. Negative clinical outcomes, 30-day mortality and 30-day recurrence stratified by delay in receiving appropriate therapy. aIndicates 0% negative clinical outcomes, 
0% 30-day mortality, and 0% 30-day recurrence.
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